This means that passive immunization with tau antibodies is actually a viable therapeutic focus on and the CSF standard of p-tau262/356 or from the microtubule binding area (MTBD) can function a handy biomarker of tau pathology to monitor tau therapeutics in scientific trials.To Jubao Duan in the College of Chicago, the authors provide persuasive p